Predictive Factors for Long-Term Disease Control in Systemic Treatment-Naïve Oligorecurrent Renal Cell Carcinoma Treated with Up-Front Stereotactic Ablative Radiotherapy (SABR)
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024, 74, 229–263. [Google Scholar] [CrossRef] [PubMed]
- Kim, S.P.; Weight, C.J.; Leibovich, B.C.; Thompson, R.H.; Costello, B.A.; Cheville, J.C.; Lohse, C.M.; Boorjian, S.A. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology 2011, 78, 1101–1106. [Google Scholar] [CrossRef] [PubMed]
- Zhan, X.; Chen, T.; Liu, Y. Trends in cause of death among patients with renal cell carcinoma in the United States: A SEER-based study. BMC Public. Health 2023, 23, 770. [Google Scholar] [CrossRef]
- Padala, S.A.; Barsouk, A.; Thandra, K.C. Epidemiology of Renal Cell Carcinoma. World J. Oncol. 2020, 11, 79–87. [Google Scholar] [CrossRef]
- Hellman, S.; Weichselbaum, R.R. Oligometastases. J. Clin. Oncol. 1995, 13, 8–10. [Google Scholar] [CrossRef]
- Palma, D.A.; Olson, R.; Harrow, S.; Gaede, S.; Louie, A.V.; Haasbeek, C.; Mulroy, L.; Lock, M.; Rodrigues, G.B.; Yaremko, B.P.; et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J. Clin. Oncol. 2020, 38, 2830–2838. [Google Scholar] [CrossRef]
- De Meerleer, G.; Khoo, V.; Escudier, B.; Joniau, S.; Bossi, A.; Ost, P.; Briganti, A.; Fonteyne, V.; Van Vulpen, M.; Lumen, N.; et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 2014, 15, e170–e177. [Google Scholar] [CrossRef] [PubMed]
- Altoos, B.; Amini, A.; Yacoub, M.; Bourlon, M.T.; Kessler, E.E.; Flaig, T.W.; Fisher, C.M.; Kavanagh, B.D.; Lam, E.T.; Karam, S.D. Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). Radiat. Oncol. 2015, 10, 218. [Google Scholar] [CrossRef] [PubMed]
- Ranck, M.C.; Golden, D.W.; Corbin, K.S.; Hasselle, M.D.; Liauw, S.L.; Stadler, W.M.; Hahn, O.M.; Weichselbaum, R.R.; Salama, J.K. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am. J. Clin. Oncol. 2013, 36, 589–595. [Google Scholar] [CrossRef]
- Franzese, C.; Franceschini, D.; Di Brina, L.; D’Agostino, G.R.; Navarria, P.; Comito, T.; Mancosu, P.; Tomatis, S.; Scorsetti, M. Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma. J. Urol. 2019, 201, 70–75. [Google Scholar] [CrossRef]
- Franzese, C.; Marini, B.; Baldaccini, D.; Badalamenti, M.; Navarria, P.; Bellu, L.; Franceschini, D.; Comito, T.; Clerici, E.; Teriaca, M.A.; et al. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma. J. Cancer Res. Clin. Oncol. 2023, 149, 4411–4417. [Google Scholar] [CrossRef] [PubMed]
- Guckenberger, M.; Lievens, Y.; Bouma, A.B.; Collette, L.; Dekker, A.; Desouza, N.M.; Dingemans, A.-M.C.; Fournier, B.; Hurkmans, C.; Lecouvet, F.E.; et al. Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet. Oncol. 2020, 21, e18–e28. [Google Scholar] [CrossRef] [PubMed]
- Powles, T.; Albiges, L.; Bex, A.; Grünwald, V.; Porta, C.; Procopio, G.; Schmidinger, M.; Suárez, C.; de Velasco, G. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann. Oncol. 2021, 32, 1511–1519. [Google Scholar] [CrossRef]
- Zaorsky, N.G.; Lehrer, E.J.; Kothari, G.; Louie, A.V.; Siva, S. Stereotactic ablative radiation therapy for oligometastatic renal cell car- cinoma (SABR ORCA): A meta-analysis of 28 studies. Eur. Urol. Oncol. 2019, 2, 515–523. [Google Scholar] [CrossRef]
- Ali, M.; Mooi, J.; Lawrentschuk, N.; McKay, R.R.; Hannan, R.; Lo, S.S.; Hall, W.A.; Siva, S. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma. Eur. Urol. 2022, 82, 613–622. [Google Scholar] [CrossRef]
- Tang, C.; Msaouel, P.; Hara, K.; Choi, H.; Le, V.; Shah, A.Y.; Wang, J.; Jonasch, E.; Choi, S.; Nguyen, Q.N.; et al. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: A single-arm, single-centre, feasibility, phase 2 trial. Lancet. Oncol. 2021, 22, 1732–1739. [Google Scholar] [CrossRef]
- Hannan, R.; Christensen, M.; Christie, A.; Garant, A.; Pedrosa, I.; Robles, L.; Mannala, S.; Wang, C.; Hammers, H.; Arafat, W.; et al. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer. Eur. Urol. Oncol. 2022, 5, 695–703. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Schoenhals, J.; Christie, A.; Mohamad, O.; Wang, C.; Bowman, I.; Singla, N.; Hammers, H.; Courtney, K.; Bagrodia, A.; et al. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. Int. J. Radiat. Oncol. Biol. Phys. 2019, 105, 367–375. [Google Scholar] [CrossRef]
- Singh, R.; Ansinelli, H.; Sharma, D.; Jenkins, J.; Davis, J.; Sharma, S.; Vargo, J.A. Stereotactic body radiation therapy (SBRT) for metastatic renal cell carcinoma: A multi-institutional experience. J. Radiosurg. SBRT. 2020, 7, 29–37. [Google Scholar]
- Franzese, C.; Marvaso, G.; Francolini, G.; Borghetti, P.; Trodella, L.E.; Sepulcri, M.; Matrone, F.; Nicosia, L.; Timon, G.; Ognibene, L.; et al. the role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: A multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group. Clin. Exp. Metastasis. 2021, 38, 527–537. [Google Scholar] [CrossRef]
- Liu, Y.; Long, W.; Zhang, Z.; Zhang, Z.; Mai, L.; Huang, S.; Han, H.; Zhou, F.; Dong, P.; He, L. Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: Extent of tumor burden eradicated by radiotherapy. World J. Urol. 2021, 39, 4183–4190. [Google Scholar] [CrossRef] [PubMed]
Treated Patients | 50 |
Treated Oligometastases | 81 |
Age, median (range) | 66 years (44–84) |
Gender | |
Female | 8 (16.0%) |
Male | 42 (84.0%) |
ECOG Performance status | |
0 | 33 (66.0%) |
1 | 15 (30.0%) |
2 | 2 (4.0%) |
Number treated metastases | |
1 | 29 (58.0%) |
2 | 15 (30.0%) |
3 | 3 (6.0%) |
4 | 2 (4.0%) |
5 | 1 (2.0%) |
Treated organs | |
1 | 41 (82.0%) |
2 | 8 (16.0%) |
3 | 1 (2.0%) |
Site of treatment | |
Bone | 4 (8%) |
Liver | 2 (4%) |
Lymph nodes | 6 (12%) |
Adrenal glands | 7 (14%) |
Pancreas | 5 (10%) |
Lung | 20 (40%) |
Lung and lymph nodes | 3 (6%) |
Lung and bone | 1 (2%) |
Lymph node and adrenal gland | 1 (2%) |
Lung and pancreas | 1 (2%) |
Disease-free interval, median (range) | 34.0 months (0–266.6) |
BED10, median (range) | 78.7 Gy (37.5–120) |
Univariate | Multivariable | |||||
---|---|---|---|---|---|---|
HR | 95% CI | p-Value | HR | 95%CI | p-Value | |
Age | 1.05 | 0.99–1.12 | 0.057 | - | - | - |
Gender, Male | 1.01 | 0.22–4.66 | 0.984 | - | - | - |
ECOG PS | 1.63 | 0.69–3.88 | 0.262 | - | - | - |
DFI | 1.00 | 0.99–1.01 | 0.253 | 1.00 | 0.99–1.01 | 0.077 |
Time to SBRT | 0.97 | 0.94–1.01 | 0.240 | 0.96 | 0.93–1.00 | 0.102 |
Single vs. multiple mets | 4.93 | 1.33–18.28 | 0.017 | 3.31 | 0.69–15.84 | 0.133 |
Number of organs | 5.30 | 1.90–14.81 | 0.001 | 3.59 | 0.99–12.98 | 0.050 |
Lung mets | 0.61 | 0.19–1.94 | 0.406 | - | - | - |
Univariate | Multivariable | |||||
---|---|---|---|---|---|---|
HR | 95% CI | p-Value | HR | 95% CI | p-Value | |
Age | 0.99 | 0.91–1.08 | 0.907 | - | - | - |
Gender, Male | - | - | - | - | - | - |
ECOG PS | 0.50 | 0.06–3.84 | 0.508 | 0.22 | 0.02–1.72 | 0.150 |
DFI | 0.98 | 0.94–1.01 | 0.268 | - | - | - |
Time to SBRT | 0.98 | 0.94–1.03 | 0.553 | - | - | - |
Single vs. multiple mets | 1.19 | 0.19–7.15 | 0.848 | - | - | - |
Number of organs | 1.83 | 0.20–16.47 | 0.588 | 5.55 | 0.40–76.59 | 0.200 |
Lung mets | 0.23 | 0.02–2.07 | 0.192 | 0.90 | 0.00–1.17 | 0.066 |
Univariate | Multivariable | |||||
---|---|---|---|---|---|---|
HR | 95%CI | p-Value | HR | 95%CI | p-Value | |
Age | 1.00 | 0.96–1.03 | 0.993 | - | - | - |
Gender, Male | 1.78 | 0.62–5.12 | 0.278 | 2.16 | 0.74–6.28 | 0.157 |
ECOG PS | 1.15 | 0.63–2.09 | 0.636 | - | - | - |
DFI | 0.99 | 0.99–1.00 | 0.872 | - | - | - |
Time to SBRT | 0.99 | 0.97–1.00 | 0.242 | - | - | - |
Single vs. multiple mets | 1.81 | 0.88–3.70 | 0.104 | 2.39 | 1.12–5.08 | 0.023 |
Number of organs | 1.32 | 0.50–3.46 | 0.566 | - | - | - |
Lung mets | 0.49 | 0.24–1.01 | 0.056 | 0.38 | 0.18–0.80 | 0.011 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Franzese, C.; Vernier, V.; Badalamenti, M.; Lucchini, R.; Stefanini, S.; Bertolini, A.; Ilieva, M.; Di Cristina, L.; Marini, B.; Franceschini, D.; et al. Predictive Factors for Long-Term Disease Control in Systemic Treatment-Naïve Oligorecurrent Renal Cell Carcinoma Treated with Up-Front Stereotactic Ablative Radiotherapy (SABR). Cancers 2024, 16, 2963. https://doi.org/10.3390/cancers16172963
Franzese C, Vernier V, Badalamenti M, Lucchini R, Stefanini S, Bertolini A, Ilieva M, Di Cristina L, Marini B, Franceschini D, et al. Predictive Factors for Long-Term Disease Control in Systemic Treatment-Naïve Oligorecurrent Renal Cell Carcinoma Treated with Up-Front Stereotactic Ablative Radiotherapy (SABR). Cancers. 2024; 16(17):2963. https://doi.org/10.3390/cancers16172963
Chicago/Turabian StyleFranzese, Ciro, Veronica Vernier, Marco Badalamenti, Raffaella Lucchini, Sara Stefanini, Anna Bertolini, Maryia Ilieva, Luciana Di Cristina, Beatrice Marini, Davide Franceschini, and et al. 2024. "Predictive Factors for Long-Term Disease Control in Systemic Treatment-Naïve Oligorecurrent Renal Cell Carcinoma Treated with Up-Front Stereotactic Ablative Radiotherapy (SABR)" Cancers 16, no. 17: 2963. https://doi.org/10.3390/cancers16172963